share_log

Goldman Sachs Maintains Buy on BrightSpring Health, Lowers Price Target to $18

Benzinga ·  Aug 9 23:39  · Ratings

Goldman Sachs analyst Jamie Perse maintains BrightSpring Health (NASDAQ:BTSG) with a Buy and lowers the price target from $21 to $18.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment